Nasdaq ardx.

Ardelyx, Inc. (NASDAQ:ARDX) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's forecasts.The analysts have sharply increased their revenue ...WALTHAM, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...Ardelyx (NASDAQ: ARDX), a biotech innovator, is arguably one of the best picks among penny stocks to buy.Its powerful portfolio, featuring IBSRELA for IBS-C and XPHOZAH for chronic kidney disease ...25 thg 8, 2023 ... Cantor Fitzgerald, by way of analyst Louise Chen, upgraded Ardelyx to “overweight” in light of a very strong potential win. The analysts expect ...

Shares of Ardelyx (NASDAQ: ARDX) were up 9.5% as of 3:47 p.m. after the biotech company announced better-than-expected third-quarter 2023 results.Ardelyx, Inc. (NASDAQ:ARDX) issued its earnings results on Tuesday, October, 31st. The biopharmaceutical company reported $0.03 EPS for the quarter, topping analysts' consensus estimates of ($0.11) by $0.14. The biopharmaceutical company earned $56.39 million during the quarter, compared to analysts' expectations of $22.09 million.EPS Estimate Trends. Current. N/A. 1 Month Ago. -$0.10. 3 Months Ago. -$0.11. Ardelyx Inc. analyst estimates, including ARDX earnings per share estimates and analyst recommendations.

Dec 29, 2022 · Ardelyx, Inc. (NASDAQ:ARDX) is a Waltham, Massachusetts-based biopharmaceutical company focused on the development of first-in-class remedies that meet significant unmet medical needs. Q1 net loss was $26.8 million, but Ardelyx raised $51.9 million through sales of their common stock at an average price of about $3.35, leaving $130.4 million in total cash and investments as of ...

Ardelyx, Inc. (NASDAQ:ARDX) BioNTech SE (NASDAQ:BNTX) Globus Medical, Inc. (NYSE:GMED) GW Pharmaceuticals plc (NASDAQ:GWPH) Medpace Holdings, Inc. (NASDAQ:MEDP) ... Qorvo (NASDAQ:QRVO) said the ...A total of 14 hedge funds in Insider Monkey’s database of hedge funds had stakes in Ardelyx Inc. (NASDAQ:ARDX). The most significant stake in Ardelyx Inc. (NASDAQ:ARDX) was owned by. 6.Real time Ardelyx (ARDX) stock price quote, stock graph, news & analysis.WALTHAM, Mass., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...Sarepta Therapeutics, Inc. Common Stock (DE) (SRPT) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.

Analysts' Revenue Estimates For Ardelyx, Inc. (NASDAQ:ARDX) Are Surging Higher Dec 02. Ardelyx Announces Launching of IBSRELA® Second Quarter of 2022 Dec 01. Insider notifies of intention to sell stock Nov 19. Third quarter 2021 earnings released: US$0.42 loss per share (vs US$0.20 loss in 3Q 2020)

Free Trial NASDAQ:ARDX Ardelyx (ARDX) Earnings Date, Estimates & Call Transcripts $4.31 -0.01 (-0.23%) (As of 04:25 PM ET) Compare Today's Range $4.20 …

And so to Ardelyx ( ARDX ). Shares were scraping the bottom in Tuesday’s trading with a massive 74% drop after the company announced it had received a letter from the FDA which suggests approval ...Citigroup Inc. decreased its position in shares of Ardelyx, Inc. (NASDAQ:ARDX – Free Report) by 49.9% in the 2nd quarter, according to the company in its most recent Form 13F filing with the ...On March 02, Ardelyx ( NASDAQ: ARDX ), now nearly a $800 million cap biopharmaceutical company reported 2022 financial results and provided a business update. Since the initial coverage, shares ...Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that Nasdaq has halted trading of the Company's common stock.AzurRx, Inc. (NASDAQ:AZRX) said due to demand, the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 9.09 million ...Ardelyx Inc (NASDAQ:ARDX) trade information. After registering a -0.23% downside in the last session, Ardelyx Inc (ARDX) has traded red over the past five days. The stock hit a weekly high of 4.49 this Wednesday, 11/22/23, dropping -0.23% in its intraday price action. The 5-day price performance for the stock is 11.37%, and 14.02% over 30 days.Back to ARDX Overview About Latest Pre-Market Trades Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day.

Ardelyx, Inc. (NASDAQ:ARDX) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's forecasts.The analysts have sharply increased their revenue ...One thing we could say about the analysts on Ardelyx, Inc. (NASDAQ:ARDX) - they aren't optimistic, having just made a major negative revision to their near-term (statutory) forecasts for the ...On this news, the Company’s stock price fell $0.70, or 13.4%, to close at $4.51 per share on May 26, 2021, on unusually heavy trading volume.The FDA approved Ardelyx Inc's (NASDAQ:ARDX) Xphozah (tenapanor), the first and only phosphate absorption inhibitor, indicated to reduce serum phosphorus in adults with chronic kidney disease (CKD ...The forecasts range from a low of 6.06 to a high of $12.60. The average price target represents an increase of 81.50% from its latest reported closing price of 4.73. leaderboard of companies with ...

Massachusetts-based Ardelyx (NASDAQ:ARDX) is another hot biotech to consider heading into 2023. All after the US FDA’s Cardiovascular and Renal Drugs Advisory Committee (CRDAC) voted in favor of ...Ardelyx, Inc. (NASDAQ:ARDX) issued its earnings results on Tuesday, October, 31st. The biopharmaceutical company reported $0.03 EPS for the quarter, topping analysts' consensus estimates of ($0.11) by $0.14. The biopharmaceutical company earned $56.39 million during the quarter, compared to analysts' expectations of $22.09 million.

Ardelyx Inc stock price (ARDX). NASDAQ: ARDX. Buying or selling a stock that's not traded in your local currency? Don't let the currency conversion trip you ...ARDX Stock Overview ... Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal ...WALTHAM, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in ...See the latest Ardelyx Inc stock price (ARDX:XNAS), related news, valuation, dividends and more to help you make your investing decisions.Ardelyx, Inc. (NASDAQ:ARDX) Q3 2023 Earnings Call Transcript (Insider Monkey) Oct-31-23 11:15PM Q3 2023 Ardelyx Inc Earnings Call (Thomson Reuters StreetEvents) +9.12%. 05:09PM Why Ardelyx Stock Soared Today (Motley Fool) 08:40AM Ardelyx (ARDX) Q3 Earnings and Revenues Top Estimates ...Oct 17, 2023 · WALTHAM, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ... WALTHAM, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...

Ardelyx Stock (NASDAQ:ARDX), Short Interest Report. Short interest for Ardelyx gives investors a sense of the degree to which investors are betting on the decline of Ardelyx's stock.

WALTHAM, Mass., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in ...

Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has accepted its resubmission of a New Drug Application (NDA) for XPHOZAH® (tenapanor) for the control of serum phosphate in adult ...According to 5 analysts, the average rating for ARDX stock is "Strong Buy." The 12-month stock price forecast is $8.7, which is an increase of 92.91% from the latest price.Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company’s lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation.Plug Power, Inc. Common Stock. $9.46 -1.29 -12.00%. Ardelyx, Inc. Common Stock (ARDX) After-Hours Stock Quotes - Nasdaq offers after-hours quotes and extended trading activity data for US and ...WALTHAM, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...ARDX Stock Overview ... Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal ...Dec 29, 2022 · Ardelyx, Inc. (NASDAQ:ARDX) is a Waltham, Massachusetts-based biopharmaceutical company focused on the development of first-in-class remedies that meet significant unmet medical needs. WALTHAM, Mass., May 01, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...

Apr 24, 2023 · Ardelyx (NASDAQ:ARDX) is a good speculative biotech to look into. That's because it has been able to generate a good amount of sales with its drug ibsrela for the treatment of adults with ... ARDX Stock 12 Months Forecast. $9.92. (177.48% Upside) Based on 7 Wall Street analysts offering 12 month price targets for Ardelyx in the last 3 months. The average price target is $9.92 with a high forecast of $12.00 and a low forecast of $7.00. The average price target represents a 177.48% change from the last price of $3.58. View Ardelyx, Inc ARDX investment & stock information. Get the latest Ardelyx, Inc ARDX detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. ... NASDAQ data is at least 15 ...Instagram:https://instagram. anthem dental insurance reviewsbest dental discount planscricketphonebroker para metatrader 4 3 Penny Stocks to Buy and Hold for the Next 10 Years. 1 month ago. Simply Wall St. 1 week ago. Ardelyx (NASDAQ:ARDX) delivers shareholders splendid 109% return over 1 year, …Sep 28, 2023 · WALTHAM, Mass., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in ... cms energy corpprinciple 401 Ardelyx, Inc. (NASDAQ:ARDX) BioNTech SE (NASDAQ:BNTX) Globus Medical, Inc. (NYSE:GMED) GW Pharmaceuticals plc (NASDAQ:GWPH) Medpace Holdings, Inc. (NASDAQ:MEDP) ... Qorvo (NASDAQ:QRVO) said the ... wba research WALTHAM, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...AzurRx, Inc. (NASDAQ:AZRX) said due to demand, the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 9.09 million ...